Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub‐Analysis of the ENABLE Study for PCa
International Journal of Urology · 2026-05 · 33 (5)
DOI: 10.1111/iju.70511 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Urology, online erschienen am 20.05.2026. Verfasst von Seiji Hoshi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Androstenes, Prostatic Neoplasms, Castration-Resistant, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Japanese Foundation for Multidisciplinary Treatment of Cancer.
Abstract (Originalsprache)
Objectives
The ENABLE study, an investigator‐initiated, multicenter, randomized controlled trial, demonstrated comparable survival benefits between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) for castration‐resistant prostate cancer (CRPC). Because randomized controlled trials typically exclude patients with a history of other cancers (HOCs), we evaluated the efficacy of these agents in this population.
Methods
This sub‐analysis was conducted as a post hoc analysis using data from the ENABLE study. Endpoints included time to PSA progression, radiographic progression‐free survival, overall survival (OS), prostate cancer‐specific survival, and safety. Outcomes were compared between patients with and without a HOC+ versus HOC− and between treatment arms within each group.
Results
The HOC+ group included 35 patients (13 ENZ, 22 ABI), whereas the HOC− group included 149 patients (79 ENZ, 70 ABI). The most frequent malignancy was gastric cancer ( n = 10, 29%). HOC+ patients had significantly worse OS than HOC− patients (median 24.7 vs. 37.4 months; HR 1.96; 95% CI 1.02–3.77; p = 0.0426), while other survival endpoints did not differ between the groups. Within the HOC+ group, OS was significantly worse with ENZ than with ABI (median 16.0 vs. 30.5 months; HR 3.27; 95% CI 1.08–9.89; p = 0.0354), whereas no significant differences were observed between the arms in the HOC− group.
Conclusions
Although OS was poorer in HOC+ patients, other outcomes were similar, supporting the feasibility of ENZ and ABI regardless of cancer history. The longer OS with ABI in HOC+ patients represents a hypothesis‐generating observation and should be interpreted with particular caution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan.
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
- Department of Urology, Toyama Prefectural Central Hospital, Toyama, Japan.
- Department of Urology, Fukui-ken Saiseikai Hospital, Fukui, Fukui, Japan.
- Department of Urology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Hiroshima, Japan.
- Department of Urology, Anjo Kosei Hospital, Anjo, Aichi, Japan.
ORCID-Profile: Seiji Hoshi, Yuki Kato, Shuichi Tatarano, Nobumichi Tanaka, Noriyasu Kawai, Kohei Hashimoto
Förderung
- Japanese Foundation for Multidisciplinary Treatment of Cancer
Zitieren
APA
Hoshi, S., Izumi, K., Meguro, S., Shima, T., Kato, Y., Mita, K., Okamura, T., Inoue, S., Tatarano, S., Tanaka, N., Yoshio, Y., Kamiyama, M., Chikazawa, I., Kawai, N., Hashimoto, K., Fukagai, T., Shigehara, K., Takahara, S., & Mizokami, A. (2026). Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub‐Analysis of the ENABLE Study for PCa. International Journal of Urology, 33(5). https://doi.org/10.1111/iju.70511
Vancouver
Hoshi S, Izumi K, Meguro S, Shima T, Kato Y, Mita K, et al. Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub‐Analysis of the ENABLE Study for PCa. International Journal of Urology. 2026;33(5). doi:10.1111/iju.70511
BibTeX
@article{Hoshi2026,
author = {Hoshi, Seiji and Izumi, Kouji and Meguro, Satoru and Shima, Takashi and Kato, Yuki and Mita, Koji and Okamura, Takehiko and Inoue, Shogo and Tatarano, Shuichi and Tanaka, Nobumichi and Yoshio, Yuko and Kamiyama, Manabu and Chikazawa, Ippei and Kawai, Noriyasu and Hashimoto, Kohei and Fukagai, Takashi and Shigehara, Kazuyoshi and Takahara, Shizuko and Mizokami, Atsushi},
title = {Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub‐Analysis of the ENABLE Study for PCa},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {5},
doi = {10.1111/iju.70511}
}
EUVIMED